SCHEMBL4772799

SCHEMBL4772799

CCOC(=O)c1ccc(Cc2cc(Cl)ccc2OCc2ccccc2)o1

nearest known ligand 0.74

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 16/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929045 0.91 PTGER1 (0.60) PTGER1
SCHEMBL4923868 0.90 PTGER1 (0.59) PTGER1
SCHEMBL4925013 0.90 PTGER1 (0.59) PTGER1
SCHEMBL4918551 0.88 PTGER1 (0.58) PTGER1
SCHEMBL4925607 0.87 PTGER1 (0.56) PTGER1
SCHEMBL4777194 0.87 PTGER1 (0.80) PTGER1
SCHEMBL4915426 0.87 PTGER1 (0.56) PTGER1
SCHEMBL4771382 0.87 PTGER1 (0.83) PTGER1
SCHEMBL4923927 0.86 PTGER1 (0.55) PTGER1
SCHEMBL4923812 0.86 PTGER1 (0.59) PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1874749-A1 FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2008-01-09 EP disclosed
WO-2006114272-A1 FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists PTGER1, PTGER2, PTGER3 PTGER1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.